Twin Tree Management’s Royalty Pharma RPRX Stock Holding History

Twin Tree Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.28M	Buy	+26,700	New	+$1.17M	0.03%	629
2025 Q3	–	Sell	-318,100	Closed	-$11.5M	–	1793
2025 Q2	$11.5M	Sell	318,100 -3,900	-1%	-$129K	0.02%	719
2025 Q1	$10M	Buy	+322,000	New	+$10.2M	0.02%	672
2024 Q2	–	Sell	-33,000	Closed	-$1M	–	1623
2024 Q1	$1M	Sell	33,000 -52,900	-62%	-$1.56M	﹤0.01%	1065
2023 Q4	$2.41M	Buy	+85,900	New	+$2.36M	﹤0.01%	1027
2023 Q3	–	Sell	-5,700	Closed	-$175K	–	1485
2023 Q2	$175K	Buy	5,700 +500	+10%	+$16.9K	﹤0.01%	1123
2023 Q1	$187K	Buy	+5,200	New	+$193K	﹤0.01%	1126
2022 Q1	–	Sell	-120,500	Closed	-$4.8M	–	1863
2021 Q4	$4.8M	Buy	+120,500	New	+$4.68M	0.01%	855

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Twin Tree Management's RPRX Position: Q2 2025 in Review

Twin Tree Management sold out of Royalty Pharma (RPRX) in Q2 2025, closing a stake of 44,763 shares — an estimated $1.48M sold.

Twin Tree Management first reported a position in RPRX in Q2 2022 and held it in 8 quarters. The position peaked at $2.79M in Q1 2024. 455 funds tracked by Wall St. Rank hold RPRX as of Q2 2025.

Twin Tree Management reported no remaining Royalty Pharma position as of Q2 2025 after selling out during the quarter.
Twin Tree Management sold 44,763 Royalty Pharma shares in Q2 2025, an estimated $1.48M.
Twin Tree Management first reported a position in Royalty Pharma in Q2 2022 and held it in 8 quarters.
Twin Tree Management's Royalty Pharma position peaked at $2.79M in Q1 2024.
455 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2025.

Based on Twin Tree Management's 13F filing for Q2 2025, filed 28 Jul 2025.